EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Long-term survival with erlotinib for lung cancer with secondary leptomeningeal carcinomatosis

Diego Neira, Paloma Ruiz, Barbara Nuñez, Gonzalo Navarrete, Rodrigo Vasquez, Luis Villanueva, Olga Barajas

Frontiers in Oncology · 14.05.2026 · 16

DOI: 10.3389/fonc.2026.1739717 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 14.05.2026. Verfasst von Diego Neira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital Clínico Universidad de Chile, Santiago, Chile. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, effective as treatment for advanced non-small cell lung cancer; however, no quality evidence of its benefit in leptomeningeal carcinomatosis has been reported. Previous case series suggest that higher doses are more effective, if higher concentrations reach the central nervous system. Here, we present the case of a 42-year-old Chilean patient with EGFR -mutant lung cancer and leptomeningeal metastasis. A multimodal treatment was performed with intrathecal chemotherapy, craniospinal radiotherapy and erlotinib (150 mg/day) for 5 years. At the time of this publication, she remained disease-free, and no EGFR mutation was detected via liquid biopsy. Further investigation is needed to determine the optimal anti EGFR regimen, the intrathecal chemotherapy protocol, and their sequencing. It is also of particular interest to identify factors associated with disease progression, and which are predictors of a good response to tyrosine kinase inhibitor among such patients.

Schlagwörter

Stichwörter der Autor:innen

EGFR tyrosine kinase inhibitorcraniospinal radiotherapyerlotinibliquid biopsylong-term survivalmeningeal carcinomatosisnon-small-cell lung cancer

Autor:innen und Institutionen

  • Department of Medical Oncology, Hospital Clínico Universidad de Chile, Santiago, Chile.
  • Department of Medical Oncology, Hospital San Juan de Dios, Santiago, Chile.
  • Departments of Medicine and Basic and Clinical Oncology and Center for Cancer Prevention and Control (CECAN), Faculty of Medicine, Universidad de Chile, Santiago, Chile.

Zitieren

APA

Neira, D., Ruiz, P., Nuñez, B., Navarrete, G., Vasquez, R., Villanueva, L., & Barajas, O. (2026). Case Report: Long-term survival with erlotinib for lung cancer with secondary leptomeningeal carcinomatosis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1739717

Vancouver

Neira D, Ruiz P, Nuñez B, Navarrete G, Vasquez R, Villanueva L, et al. Case Report: Long-term survival with erlotinib for lung cancer with secondary leptomeningeal carcinomatosis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1739717

BibTeX
@article{Neira2026,
  author = {Neira, Diego and Ruiz, Paloma and Nuñez, Barbara and Navarrete, Gonzalo and Vasquez, Rodrigo and Villanueva, Luis and Barajas, Olga},
  title = {Case Report: Long-term survival with erlotinib for lung cancer with secondary leptomeningeal carcinomatosis},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1739717}
}
Kostenlos starten →